Journal
ONCOLOGIST
Volume 10, Issue 6, Pages 382-391Publisher
WILEY
DOI: 10.1634/theoncologist.10-6-382
Keywords
angiogenesis; lung cancer; VEGF; vascular endothelial growth factor; colorectal cancer; breast cancer; bevacizumab; vatalanib; PTK787
Categories
Ask authors/readers for more resources
After over 30 years of theorizing, the use of angiogenesis inhibitors as anticancer therapy has finally moved from the realm of research to reality. Normal adult vasculature is generally quiescent in nature, with endothelial cells dividing approximately every 10 years. In contrast, the growth of tumors requires constant vascular growth and remodeling in order for solid tumors to grow beyond 1-2 mm(3) in size. Vascular endothelial growth factor (VEGF) and its receptors are key regulators of the process of angiogenesis, which makes them attractive therapeutic targets. A multitude of VEGF-targeted inhibitory agents are currently being investigated for the treatment of cancer. This review article focuses on recent developments in the use of angiogenesis inhibitors for the treatment of breast, lung, and colorectal cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available